SHIEF
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | -0.01 | $28M | -$13M |
| 2025 Q2 | -0.01 | $21M | $8M |
| 2024 Q4 | -0.01 | $9M | -$2M |
| 2024 Q2 | -0.01 | $6M | -$2M |
| 2023 Q4 | -0.01 | $9M | -$9M |
| 2023 Q2 | -0.01 | $2M | -$10M |
| 2022 Q4 | -0.12 | $2M | -$10M |
| 2022 Q2 | -0.05 | $2M | -$10M |